Tissue Engineered Stents

• US 20060122695A1
• Filed: 01/26/2006
• Published: 06/08/2006
• Est. Priority Date: 04/28/2000
• Status: Abandoned Application

• Current Assignee: Children's Medical Center Corporation
• Original Assignee: Children's Medical Center Corporation
• Inventors: Atala, Anthony
• Application Number:
  US11/339,872
• Publication Number:
  US 20060122695A1
• Time in Patent Office: Days
• US Class Current: 623/1.380
• CPC Class Codes: A61F 2/02 Prostheses implantable into the body closure means for urethra or rectum or for artificial body openings therefor A61F2/0004
• CPC Class Codes: A61K 35/12 Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells vaccines or medicinal preparations containing antigens or antibodies A61K39/00
• CPC Class Codes: A61L 27/18 obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
• CPC Class Codes: A61L 27/3817 Cartilage-forming cells, e.g. pre-chondrocytes
• CPC Class Codes: A61L 27/58 Materials at least partially resorbable by the body
• CPC Class Codes: A61L 31/005 Ingredients of undetermined constitution or reaction products thereof
• CPC Class Codes: A61L 31/06 obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds A61L31/041 takes precedence
• CPC Class Codes: A61L 31/145 Hydrogels or hydrocolloids
• CPC Class Codes: C08L 67/04 Polyesters derived from hydroxycarboxylic acids, e.g. lactones C08L67/06 takes precedence
• CPC Class Codes: C12N 2533/40 Polyhydroxyacids, e.g. polymers of glycolic or lactic acid (PGA, PLA, PLGA); Bioresorbable polymers
• CPC Class Codes: C12N 5/0655 Chondrocytes; Cartilage

Abstract

This invention is directed to a tissue-engineered stent comprising a substantially cylindrical construct (10) having a first end (12) and a second end (14); a walled surface (16) disposed between the first end and the second end; the walled surface (16) comprising a biodegradable polymer scaffold seeded with disassociated chondrocytes. In one embodiment, the seeded scaffold is cultured in vitro prior to implantation in a host for a time period sufficient for cartilaginous tissue to form.

Claims

1. A method for producing a tissue engineered stent comprising the steps of:

(a) providing a substrate shaped to form a substantially cylindrical construct, the substrate comprising a biodegradable polymer;

(b) contacting said substrate with dissociated chondrocytes capable of adhering thereto and forming cartilage, thereby forming a cell-seeded construct;

(c) maintaining said cell-seeded construct for a growth period in a fluid media suitable for growth of said chondrocytes to form a tissue-engineered stent, wherein the stent is designed to be implanted for the treatment of stricture diseases involving urethra, ureters, blood vessels, biliary ducts, intestines, airways of the lungs and fallopian tubes.

2. The method of claim 1, wherein said chondrocytes are autologous, allogenic or xenogenic.

3. The method of claim 1, wherein said chondrocytes are autologous.

6. The method of claim 1, wherein the biodegradable polymer is polyglycolic acid, poly(lactide-co-glycolide) (PLGA), or a copolymer thereof.

4. A method for producing a tissue engineered stent comprising the steps of:

a. providing a substrate shaped to form a substantially cylindrical construct, the substrate comprising a biodegradable polymer;

b. contacting said substrate with dissociated chondrocytes expanded in vitro, and capable of adhering thereto and forming cartilage, thereby forming a cell-seeded construct;

c. maintaining said cell-seeded construct for a growth period in a fluid media suitable for growth of said chondrocytes to form a tissue-engineered stent, wherein the stent is designed to be implanted for the treatment of stricture diseases involving urethra, ureters, blood vessels, biliary ducts, intestines, airways of the lungs and fallopian tubes.

5. The method of claim 4, wherein the dissociated chondrocytes are present in an amount sufficient to form cartilage.

7. The method of claim 4, wherein the biodegradable polymer is polyglycolic acid, poly(lactide-co-glycolide) (PLGA), or a copolymer thereof.

8. A tissue engineered stent comprising a substantially cylindrical construct having a first end and second end;

a walled surface disposed between the first end and the second end, wherein the walled surface comprises a biodegradable polymer scaffold seeded with disassociated chondrocytes, wherein the stent is designed to be implanted for the treatment of stricture diseases involving urethra, ureters, blood vessels, biliary ducts, intestines, airways of the lungs and fallopian tubes.

9. The tissue engineered stent of claim 8, wherein the disassociated chondrocytes have been expanded in vitro.

10. The tissue engineered stent of claim 8, wherein the biodegradable polymer is polyglycolic acid, poly(lactide-co-glycolide) (PLGA), or a copolymer thereof.

11. The tissue engineered stent of claim 9, wherein the biodegradable polymer is polyglycolic acid, poly(lactide-co-glycolide) (PLGA), or a copolymer thereof.